London: Eight out of 10 antibody therapy available for treatment of Covid-19 patients do not inhibit the new and emerging sub-variants of Omicron such as BA.2.12.1, BA.4, and BA.5, according to a study published in The Lancet Infectious Diseases. A team of researchers, including those from the German Primate Center (DPZ)-Leibniz Institute for Primate Research […]
